123 related articles for article (PubMed ID: 37938166)
1. Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
Schallenberg S; Plage H; Hofbauer S; Furlano K; Weinberger S; Bruch PG; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Horst D; Klatte T; Schlomm T; Zecha H
Acta Oncol; 2023 Dec; 62(12):1880-1889. PubMed ID: 37938166
[TBL] [Abstract][Full Text] [Related]
2. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder.
Plage H; Samtleben H; Hofbauer S; Kornienko K; Weinberger S; Bruch PG; Elezkurtaj S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Klatte T; Schlomm T; Horst D; Zecha H
Hum Pathol; 2022 Dec; 130():10-17. PubMed ID: 36152841
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
4. Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
Kaczmarek K; Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Schallenberg S; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Zecha H
Int Urol Nephrol; 2024 Feb; 56(2):499-508. PubMed ID: 37777995
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers.
Korkolopoulou P; Christodoulou P; Lazaris A; Thomas-Tsagli E; Kapralos P; Papanikolaou A; Kalliteraki I; Davaris P
Eur Urol; 2001 Feb; 39(2):167-77. PubMed ID: 11223676
[TBL] [Abstract][Full Text] [Related]
6. βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer.
Hinsch A; Chaker A; Burdelski C; Koop C; Tsourlakis MC; Steurer S; Rink M; Eichenauer TS; Wilczak W; Wittmer C; Fisch M; Simon R; Sauter G; Büschek F; Clauditz T; Minner S; Jacobsen F
Hum Pathol; 2017 Mar; 61():210-220. PubMed ID: 28025079
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
[TBL] [Abstract][Full Text] [Related]
8. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
9. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.
Hitchings AW; Kumar M; Jordan S; Nargund V; Martin J; Berney DM
Br J Cancer; 2004 Aug; 91(3):552-7. PubMed ID: 15226775
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of p16 staining in malignant tumors.
De Wispelaere N; Rico SD; Bauer M; Luebke AM; Kluth M; Büscheck F; Hube-Magg C; Höflmayer D; Gorbokon N; Weidemann S; Möller K; Fraune C; Bernreuther C; Simon R; Kähler C; Menz A; Hinsch A; Jacobsen F; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Steurer S; Burandt E; Krech R; Dum D; Krech T; Marx A; Minner S
PLoS One; 2022; 17(7):e0262877. PubMed ID: 35862385
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
12. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
13. p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
Sachdeva S; Suresh PK; Basavaiah SH; Sahu KK; Sreeram S; Kini H; Kini JR; Pinto AC
J Cancer Res Ther; 2023; 19(5):1330-1334. PubMed ID: 37787303
[TBL] [Abstract][Full Text] [Related]
14. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
15. p53 and p16
Mohanty SK; Mishra SK; Bhardwaj N; Sardana R; Jaiswal S; Pattnaik N; Pradhan D; Sharma S; Kaushal S; Baisakh MR; Das S; Pradhan MR; Satapathy K; Pattnaik A; Sharma SK; Khadenga CR; Das S; Rath D; Nanda B; Parwani AV
Clin Genitourin Cancer; 2021 Dec; 19(6):510-520. PubMed ID: 34348854
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
17. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
18. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
[TBL] [Abstract][Full Text] [Related]
19. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
20. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ.
Yin M; Bastacky S; Parwani AV; McHale T; Dhir R
Hum Pathol; 2008 Apr; 39(4):527-35. PubMed ID: 18234280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
